{"product_id":"sskn-vrio-analysis","title":"STRATA Skin Sciences, Inc. (SSKN): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eUnlock the secrets to STRATA Skin Sciences, Inc. (SSKN)'s market edge with this sharp VRIO analysis. We distill whether its core assets are truly Valuable, Rare, Inimitable, and Organized for lasting success. Dive in below to see the definitive verdict on its sustainable competitive advantage.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eSTRATA Skin Sciences, Inc. (SSKN) - VRIO Analysis: 1. Patented Combination Therapy Methods (XTRAC + Systemic Drugs)\n\u003c\/h2\u003e\n\u003cp\u003eYou're looking at the core of STRATA Skin Sciences, Inc.'s current market defense: their intellectual property around combining the XTRAC laser with modern systemic drugs like JAK inhibitors. Honestly, this IP is what separates them from competitors trying to capture the same patient pool, especially as the company navigates a period where Q3 2025 revenue came in at \u003cstrong\u003e$6.93 million\u003c\/strong\u003e, showing the need to protect high-margin revenue streams.\u003c\/p\u003e\n\n\u003ch3\u003eValue: Synergistic Treatment Protocols\u003c\/h3\u003e\n\u003cp\u003eThe value here is clear: these method-of-use patents secure exclusivity for treatment protocols that combine your XTRAC laser therapy with powerful systemic drugs, including JAK inhibitors and biologics. This synergy aims for better patient outcomes and, critically, drives higher adoption among the approximately \u003cstrong\u003e1,200\u003c\/strong\u003e U.S. dermatology clinics that use excimer laser therapy. The goal is to establish a new standard of care for conditions like vitiligo and psoriasis, which is supported by new peer-reviewed studies validating the combination's efficacy.\u003c\/p\u003e\n\n\u003ch3\u003eRarity: Exclusive Combination Rights\u003c\/h3\u003e\n\u003cp\u003eThe specific, granted worldwide method-of-use patents protecting this drug\/light therapy combination are genuinely rare in this niche dermatology device space. STRATA Skin Sciences, Inc. currently holds three key granted patents related to this, including the worldwide patent WO2021053673A1, which covers the localized treatment using both UVB light and at least one systemic drug. This pioneering protection around the combined use of device-based precision and systemic immune modulation is what sets their offering apart right now. \u003c\/p\u003e\n\n\u003ch3\u003eImitability: Patent Strength vs. Concept\u003c\/h3\u003e\n\u003cp\u003eWhile the general concept of combining therapies is something competitors could try to copy, the specific claims protected by the granted patents make direct imitation difficult and legally risky. STRATA Skin Sciences, Inc. is actively demonstrating this low imitability through their defensive litigation against LaserOptek, where they successfully added LaserOptek Korea as a defendant. This enforcement action signals to the market that the specific methods are legally ring-fenced, even if the underlying technology concept is known.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization: Active Enforcement and Partnership Growth\u003c\/h3\u003e\n\u003cp\u003eThe organization appears strong in defending this asset, evidenced by the active and successful litigation to enforce these rights. The positive outcome in court has already translated into business wins: over \u003cstrong\u003e20\u003c\/strong\u003e former LaserOptek Pallas customers have switched to STRATA Skin Sciences, Inc.'s XTRAC technology, which represents over \u003cstrong\u003e$1 million\u003c\/strong\u003e in annualized revenue. Furthermore, as of June 30, 2025, \u003cstrong\u003e844\u003c\/strong\u003e clinics were already enrolled in their partnership program, showing they are organized to capitalize on this protected market space.\u003c\/p\u003e\n\n\u003ch3\u003eCompetitive Advantage Assessment\u003c\/h3\u003e\n\u003cp\u003eThe competitive advantage is currently sustained, but it is inherently temporary because patents have expiration dates. For now, the active enforcement and near-term exclusivity - especially with the AMA CPT Board reaffirming exclusive excimer use under codes 96920-96922 through January 2027 - provide a significant moat. You need to assume this advantage will erode when the patents lapse, so maximizing revenue now is defintely the priority. \u003c\/p\u003e\n\n\u003cp\u003eHere’s the quick math on the current competitive standing based on this resource:\u003c\/p\u003e\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eVRIO Dimension\u003c\/td\u003e\n    \u003ctd\u003eAssessment\u003c\/td\u003e\n    \u003ctd\u003eKey Supporting Data Point (2025)\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eValue\u003c\/td\u003e\n    \u003ctd\u003eYes\u003c\/td\u003e\n    \u003ctd\u003eAims to capture expanded CPT codes, potentially tripling the covered patient population.\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eRarity\u003c\/td\u003e\n    \u003ctd\u003eYes\u003c\/td\u003e\n    \u003ctd\u003eHolds three key granted patents, including worldwide method of use patent WO2021053673A1.\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eInimitability\u003c\/td\u003e\n    \u003ctd\u003eHigh (Legal)\u003c\/td\u003e\n    \u003ctd\u003eActive litigation against LaserOptek demonstrates legal barriers to entry.\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eOrganization\u003c\/td\u003e\n    \u003ctd\u003eStrong\u003c\/td\u003e\n    \u003ctd\u003eConverted \u0026gt;\u003cstrong\u003e20\u003c\/strong\u003e former competitor users, adding \u0026gt;\u003cstrong\u003e$1 million\u003c\/strong\u003e in annualized revenue.\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eCompetitive Advantage\u003c\/td\u003e\n    \u003ctd\u003eSustained (Temporary)\u003c\/td\u003e\n    \u003ctd\u003eExclusivity reinforced by CPT code reaffirmation through January 2027.\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eWhat this estimate hides is the risk associated with the company's overall cash position, as Q3 2025 showed a net loss of \u003cstrong\u003e$1.6 million\u003c\/strong\u003e, meaning they need these protected revenue streams to mature quickly.\u003c\/p\u003e\n\n\u003cp\u003eKey facts underpinning this analysis:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eGross profit margin for Q3 2025 was \u003cstrong\u003e60%\u003c\/strong\u003e.\u003c\/li\u003e\n  \u003cli\u003eThe company ended Q3 2025 with \u003cstrong\u003e$7.1 million\u003c\/strong\u003e in cash.\u003c\/li\u003e\n  \u003cli\u003eThe partnership program covered \u003cstrong\u003e844\u003c\/strong\u003e clinics as of June 30, 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFinance: draft 13-week cash view by Friday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eSTRATA Skin Sciences, Inc. (SSKN) - VRIO Analysis: 2. XTRAC Excimer Laser Technology Platform\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Provides the core, FDA-cleared hardware platform for treating chronic skin conditions like psoriasis, forming the base for recurring revenue streams.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; other UVB\/laser devices exist, but the XTRAC's specific 308-nanometer delivery system has established clinical use. The XTRAC excimer laser is cleared to treat psoriasis, vitiligo, eczema, atopic dermatitis and leukoderma - skin diseases that impact over \u003cstrong\u003e35 million patients\u003c\/strong\u003e in the United States alone.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate; the core hardware is imitable, but the established clinical data and installed base are harder to replicate quickly.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Well-organized to support the installed base through the Partnership Program, maintaining utilization.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; the technology itself is mature, but its integration with new drug protocols keeps it relevant.\u003c\/p\u003e\n\u003cp\u003eThe XTRAC platform supports the recurring revenue model, where the system is placed in the physician's office for no upfront charge, generating revenue on a per-use basis. The company is actively managing the installed base to improve utilization metrics.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003ePeriod\/Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDomestic Installed Base (Units)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e864\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eEnd of Q4 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDomestic Installed Base (Units)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e873\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSeptember 30, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDomestic Installed Base (Units)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e909\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eDecember 31, 2022\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAverage Net Revenue Per Domestic System\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$5,906\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ4 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAverage Net Revenue Per Domestic System Growth (YoY)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e+6%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ4 2024 vs. prior year period\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross Domestic XTRAC Recurring Billings\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$4.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross Domestic XTRAC Recurring Billings Change (YoY)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e-2%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 2024 vs. Q3 2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal Net Recurring XTRAC Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$5.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ4 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInternational Business Sales\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ1 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe organization supports utilization through Direct-to-Consumer (DTC) marketing efforts, which drive patient volume:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eIn Q1 2025, over \u003cstrong\u003e1,000 appointments\u003c\/strong\u003e were generated through DTC efforts.\u003c\/li\u003e\n\u003cli\u003eThe number of unique patients for whom STRATA handled insurance benefits increased by \u003cstrong\u003e33% YoY\u003c\/strong\u003e in Q1 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eSTRATA Skin Sciences, Inc. (SSKN) - VRIO Analysis: 3. CPT Code Reimbursement Expansion Strategy\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The pending expansion of CPT codes is projected to triple the US addressable patient population for their technology, expanding the total available market to over \u003cstrong\u003e30 million\u003c\/strong\u003e patients. This expansion is set to become effective \u003cstrong\u003eJanuary 1, 2027\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Successfully influencing CPT code expansion to cover new indications is a significant regulatory\/advocacy achievement.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e This is a regulatory moat built through years of clinical data submission and lobbying efforts.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High, as management is actively pursuing inclusion in the CMS physician fee schedule for the \u003cstrong\u003e2026\u003c\/strong\u003e cycle.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained, as this regulatory\/reimbursement advantage creates a massive barrier to entry for new competitors. The AMA CPT Board reaffirmed the exclusive use of excimer lasers under codes 96920–96922 through \u003cstrong\u003eJanuary 1, 2027\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eThe immediate impact of the CY \u003cstrong\u003e2026\u003c\/strong\u003e Medicare Physician Fee Schedule Final Rule includes a confirmed payment increase for existing indications:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\/Date\u003c\/th\u003e\n\u003cth\u003eReference\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCY 2026 Payment Increase (CPT 96920–96922)\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e3.5%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCPT Code Expansion Effective Date\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eJanuary 1, 2027\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExcimer Laser Exclusivity Under Current Codes\u003c\/td\u003e\n\u003ctd\u003eThrough \u003cstrong\u003eJanuary 1, 2027\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProjected New Addressable Patient Population\u003c\/td\u003e\n\u003ctd\u003eOver \u003cstrong\u003e30 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe current operational scale supporting this strategy includes:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eExisting partner network of over \u003cstrong\u003e840 clinics\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eTotal U.S. partner clinics operating excimer laser technology: \u003cstrong\u003e838\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eAverage gross billings per device for all U.S. partner clinics in Q3 2025: \u003cstrong\u003e$5,981\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eLitigation recovery from LaserOptek buyers representing over \u003cstrong\u003e$1 million\u003c\/strong\u003e in annual capital and recurring revenue.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eSTRATA Skin Sciences, Inc. (SSKN) - VRIO Analysis: 4. U.S. Partnership Program \u0026amp; Elevate 360 Model\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Shifts capital expenditure risk to partners via a fee-per-treatment model, ensuring a steady stream of recurring revenue and high device utilization. The fee-per-treatment structure supports recurring revenue streams based on utilization.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; fee-per-use models exist, but the specific combination of training, service, and co-op advertising support within the Elevate 360 framework is unique.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate; competitors can copy the fee-per-use structure, but replicating the established network and the proven success metrics of the E360 model is difficult.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eContext\/Period\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal U.S. XTRAC Installed Base (Devices\/Clinics)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e838\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 2025 (Pruned Installed Base)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eApproximate Total U.S. Partner Clinics (Usage Agreement)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e844\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSince early 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eElevate 360 Program Adoption (Clinics)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e99\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSince beginning of 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eE360 Adoption Rate (of 838 base)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e11.8%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e99 out of 838\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Strong; the organization has successfully implemented the program across a significant portion of its base, demonstrating tangible results for early adopters.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eAverage gross billings per device for all \u003cstrong\u003e838\u003c\/strong\u003e U.S. partner clinics reached \u003cstrong\u003e\\$5,981\u003c\/strong\u003e for Q3 2025.\u003c\/li\u003e\n\u003cli\u003eThis Q3 2025 average gross billings per device represents an \u003cstrong\u003e8.5%\u003c\/strong\u003e year-over-year increase versus Q3 2024.\u003c\/li\u003e\n\u003cli\u003ePartner clinics adopting the Elevate 360 program have shown an average year-over-year growth of \u003cstrong\u003e7%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eA specific partner expanded from \u003cstrong\u003e2\u003c\/strong\u003e clinics to \u003cstrong\u003e9\u003c\/strong\u003e clinics after adopting E360, with revenue contribution to STRATA increasing from \u003cstrong\u003e\\$10,500\u003c\/strong\u003e (H1 2024) to \u003cstrong\u003e\\$61,800\u003c\/strong\u003e (H1 2025).\u003c\/li\u003e\n\u003cli\u003eThe revenue contribution increase for the case study partner was tenfold.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; the established network of partner clinics provides a short-term advantage in deployment and data collection, but the core consulting model structure is not inherently impossible for competitors to copy.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eSTRATA Skin Sciences, Inc. (SSKN) - VRIO Analysis: 5. Direct-to-Consumer (DTC) Lead Generation Engine\n\u003c\/h2\u003e\n\u003ch\u003eValue\u003c\/h\u003e\n\u003cp\u003eDirectly drives patient demand to partner clinics, increasing device utilization and, consequently, STRATA Skin Sciences recurring revenue. The DTC strategy is linked to significant patient volume increases.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eContext\/Comparison\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatient Appointments from DTC\u003c\/td\u003e\n\u003ctd\u003eOver \u003cstrong\u003e1,000\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eQ1 2025 alone\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUnique Psoriasis Patients (DTC Impact)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e32%\u003c\/strong\u003e increase\u003c\/td\u003e\n\u003ctd\u003eYear-over-year\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUnique Acne Patients (DTC Impact)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e128%\u003c\/strong\u003e increase\u003c\/td\u003e\n\u003ctd\u003eYear-over-year\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Unique Patients (Insurance Handled)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e33%\u003c\/strong\u003e increase YoY\u003c\/td\u003e\n\u003ctd\u003eCombination of organic and DTC growth\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTheraClearX Installed Base (US)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e160\u003c\/strong\u003e devices\u003c\/td\u003e\n\u003ctd\u003eEnd of Q1 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEstimated Patient Revenue per Treatment Cycle\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$300 to $360\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eBased on $50 to $60 per treatment $\\times$ 6 treatments\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003cp\u003eLow; many med-tech firms use DTC, but STRATA's focus is highly targeted to their specific installed base. The reported patient growth metrics show significant year-over-year acceleration in patient acquisition through this channel.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eUnique Psoriasis Patients driven by DTC: \u003cstrong\u003e32%\u003c\/strong\u003e increase YoY in Q1 2025.\u003c\/li\u003e\n\u003cli\u003eUnique Acne Patients driven by DTC: \u003cstrong\u003e128%\u003c\/strong\u003e increase YoY in Q1 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003cp\u003eHigh; digital marketing tactics are widely available, though execution quality varies. The specific patient volume generated suggests a high level of current execution effectiveness.\u003c\/p\u003e\n\u003cp\u003eSTRATA Skin Sciences Q1 2025 Total Revenue was $\u003cstrong\u003e6.8 million\u003c\/strong\u003e, up \u003cstrong\u003e1%\u003c\/strong\u003e year-over-year.\u003c\/p\u003e\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003cp\u003eEffective; DTC efforts generated over 1,000 patient appointments in Q1 2025 alone. The organization supports this engine through cost control and operational efficiency improvements.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eGross Margin improved to \u003cstrong\u003e53.5%\u003c\/strong\u003e in Q1 2025 from \u003cstrong\u003e45.6%\u003c\/strong\u003e in Q1 2024.\u003c\/li\u003e\n\u003cli\u003eTotal Operating Expenses decreased by \u003cstrong\u003e5%\u003c\/strong\u003e YoY to $\u003cstrong\u003e5.7 million\u003c\/strong\u003e in Q1 2025.\u003c\/li\u003e\n\u003cli\u003eNet Loss reduced to $\u003cstrong\u003e2.4 million\u003c\/strong\u003e in Q1 2025 from $\u003cstrong\u003e3.4 million\u003c\/strong\u003e in Q1 2024.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003cp\u003eTemporary; relies on execution quality and budget, not a unique structural asset. The ability to generate a \u003cstrong\u003e128%\u003c\/strong\u003e increase in unique Acne patients via DTC in Q1 2025 demonstrates current execution strength.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eSTRATA Skin Sciences, Inc. (SSKN) - VRIO Analysis: 6. Defensive Litigation \u0026amp; Competitive Barrier Enforcement\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Protects market share and intellectual property by legally challenging competitors making misleading claims about reimbursement or technology equivalence.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; active litigation is common, but securing preliminary injunctions against key competitors is less frequent.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low; requires significant legal resources and a strong IP foundation to pursue effectively.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Strong; the company successfully added LaserOptek Korea as a defendant and secured injunctions against false advertising.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; litigation success provides a short-term shield, but it is costly and time-consuming.\u003c\/p\u003e\n\u003cp\u003eThe company secured a partial preliminary injunction from the U.S. District Court for the Eastern District of Pennsylvania on \u003cstrong\u003eNovember 8, 2024\u003c\/strong\u003e. This ruling specifically enjoined LaserOptek and The Pinnacle Health Group from marketing Pallas laser systems in the United States implying reimbursement under \u003cstrong\u003eCPT Codes 96920–96922\u003c\/strong\u003e. The Court also agreed to add LaserOptek Korea as a defendant in a subsequent decision.\u003c\/p\u003e\n\u003cp\u003eThe American Medical Association CPT Board reaffirmed the exclusive use of excimer lasers under codes \u003cstrong\u003e96920-96922\u003c\/strong\u003e through \u003cstrong\u003eJanuary 2027\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eThe impact of the litigation success included the recovery of former competitor customers:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eOver \u003cstrong\u003e20\u003c\/strong\u003e former LaserOptek Pallas buyers partnered with STRATA on XTRAC excimer laser technology or purchased XTRAC excimer lasers.\u003c\/li\u003e\n\u003cli\u003eThis customer acquisition represented over \u003cstrong\u003e$1 million\u003c\/strong\u003e in annualized revenue.\u003c\/li\u003e\n\u003cli\u003eAs of May 2025, \u003cstrong\u003e844\u003c\/strong\u003e clinics participated in STRATA's XTRAC partnership program.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe financial commitment to this enforcement included approximately \u003cstrong\u003e~$340 thousand\u003c\/strong\u003e in legal expenses paid in the second quarter of 2025 for cases the Company chose to pursue, primarily against LaserOptek.\u003c\/p\u003e\n\u003cp\u003eLitigation and Financial Context:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eAmount\/Value\u003c\/td\u003e\n\u003ctd\u003ePeriod\/Date\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePreliminary Injunction Date\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eNovember 8, 2024\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCourt Order Date\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCPT Codes Restricted\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e96920–96922\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eScope of Injunction\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRecovered Annualized Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\u0026gt;$1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ePost-Injunction Acquisition\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFormer Competitor Customers Recovered\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\u0026gt;20\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ePost-Injunction Acquisition\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLegal Expenses Paid (LaserOptek focus)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e~$340 thousand\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ2 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eXTRAC Partnership Clinics\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e844\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of May 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ4 2024 Gross Profit Margin\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e60.1%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ4 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash on Hand\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$7.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eEnd of Q3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003eSTRATA Skin Sciences, Inc. (SSKN) - VRIO Analysis: 7. TheraClearX International Commercialization Footprint\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Provides a secondary growth vector outside the core XTRAC business, diversifying revenue risk and leveraging existing international distribution channels.\u003c\/p\u003e\n\u003cp\u003eThe potential market size in Mexico for acne, psoriasis, and vitiligo is estimated at nearly \u003cstrong\u003e$300 million\u003c\/strong\u003e, with \u003cstrong\u003e80%\u003c\/strong\u003e of the Mexican population affected by low to severe acne. International Business for STRATA reported sales of \u003cstrong\u003e$2.5 million\u003c\/strong\u003e, an increase of \u003cstrong\u003e8%\u003c\/strong\u003e Year-over-Year (YoY). The breakeven point for a TheraClearX device is approximately \u003cstrong\u003e$9,000\u003c\/strong\u003e annually, requiring about \u003cstrong\u003e50\u003c\/strong\u003e procedures per quarter or \u003cstrong\u003e200\u003c\/strong\u003e per year.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Low; having a second product line is standard, but its specific international traction is what matters.\u003c\/p\u003e\n\u003cp\u003eThe TheraClearX device installed base in the U.S. reached \u003cstrong\u003e160\u003c\/strong\u003e units by the end of Q1 2025, up from \u003cstrong\u003e104\u003c\/strong\u003e devices in Q1 2024. In Q1 2023, the company sold over \u003cstrong\u003e3,000\u003c\/strong\u003e TheraClearX treatments.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate; the product is new to some markets, but establishing distribution takes time.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eTheraClearX Device Placement Milestones:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e58\u003c\/strong\u003e TheraClearX devices in the U.S. as of March 31, 2023.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e44\u003c\/strong\u003e TheraClearX devices placed in the U.S. in Q1 2023 alone.\u003c\/li\u003e\n\u003cli\u003eOver \u003cstrong\u003e100\u003c\/strong\u003e TheraClearX devices installed by the end of Q1 2024.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Emerging; initial commercial placement in Mexico was announced, showing intent to expand beyond the US.\u003c\/p\u003e\n\u003cp\u003eSTRATA Skin Sciences received regulatory clearance from Mexico's health authority, COFEPRIS, for TheraClearX, valid through November 2029 under Device Registration No. \u003cstrong\u003e3187E2024SSA\u003c\/strong\u003e. The commercial rollout in Mexico is in partnership with MINO Labs. The first TheraClearX system in Mexico was placed with Dr. Melissa Lomelí Canedo in Mexico City.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eTheraClearX Device Footprint and Revenue Contribution:\u003c\/strong\u003e\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003ePeriod Reference\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. Installed Base (Latest Reported)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e160\u003c\/strong\u003e units\u003c\/td\u003e\n\u003ctd\u003eEnd of Q1 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. Installed Base (Prior Period)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e104\u003c\/strong\u003e units\u003c\/td\u003e\n\u003ctd\u003eEnd of Q1 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Recurring Revenue Contribution\u003c\/td\u003e\n\u003ctd\u003eIncreased \u003cstrong\u003e3.0%\u003c\/strong\u003e to \u003cstrong\u003e$5.8 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eQ4 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTheraClearX Treatments Sold\u003c\/td\u003e\n\u003ctd\u003eOver \u003cstrong\u003e3,000\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eQ1 2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; this is an early-stage asset whose advantage depends on rapid international scaling.\u003c\/p\u003e\n\u003cp\u003eThe international expansion is supported by an exclusive agreement with MINO Labs for distribution in Mexico. The total Recurring revenue for Q4 2024 was \u003cstrong\u003e$5.8 million\u003c\/strong\u003e, with international growth of \u003cstrong\u003e13%\u003c\/strong\u003e in Global net recurring XTRAC® revenue offsetting a slight domestic decline.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eSTRATA Skin Sciences, Inc. (SSKN) - VRIO Analysis: 8. Recurring Revenue Optimization (High Gross Margin\/Device Billings)\n\u003c\/h2\u003e\n\u003cp\u003e\n\u003c\/p\u003e\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003eFocuses the business on high-margin, predictable revenue over one-time equipment sales, improving overall profitability metrics.\u003c\/p\u003e\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003eModerate; many device companies strive for this, but STRATA is showing tangible success in Q3 2025.\u003c\/p\u003e\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003eModerate; requires operational discipline to manage the service\/consumables side effectively.\u003c\/p\u003e\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eStrong; Gross Margin was \u003cstrong\u003e60%\u003c\/strong\u003e in Q3 2025, and average gross billings per device hit \u003cstrong\u003e$5,981\u003c\/strong\u003e in that same quarter.\u003c\/p\u003e\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003eTemporary; sustained by operational excellence, which can be eroded by market shifts or poor management.\u003c\/p\u003e\n\n\u003cp\u003e\nSTRATA Skin Sciences, Inc. reported the following financial metrics for the third quarter ended September 30, 2025:\n\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eAmount\/Rate\u003c\/td\u003e\n\u003ctd\u003ePeriod\/Comparison\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross Margin\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e60%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 2025 Revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAverage Gross Billings Per Device\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$5,981\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 2025 (U.S. Partner Clinics)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eYoY Increase in Avg. Gross Billings Per Device\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e8.5%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 2025 vs. Q3 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal Recurring Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$5.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal Recurring Revenue Growth\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e3%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eYoY for Q3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEquipment Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEquipment Revenue Decline\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e60%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eYoY for Q3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$6.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdjusted EBITDA\u003c\/td\u003e\n\u003ctd\u003eSlightly positive (\u003cstrong\u003e$10,000\u003c\/strong\u003e)\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\nSupporting operational and utilization data points for Q3 2025:\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eU.S. XTRAC install base: \u003cstrong\u003e838\u003c\/strong\u003e devices.\u003c\/li\u003e\n\u003cli\u003eAverage gross billings per device of \u003cstrong\u003e$5,981\u003c\/strong\u003e represents the highest quarterly figure since Q4 2022.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e99\u003c\/strong\u003e of approximately \u003cstrong\u003e838\u003c\/strong\u003e U.S. partner clinics entered the Elevate 360 program since the beginning of 2025.\u003c\/li\u003e\n\u003cli\u003eBusinesses completing Elevate 360 review showed an average of \u003cstrong\u003e7%\u003c\/strong\u003e growth year-over-year.\u003c\/li\u003e\n\u003cli\u003eNet loss narrowed to $(\u003cstrong\u003e1.6 million\u003c\/strong\u003e) in Q3 2025, compared to $(\u003cstrong\u003e2.1 million\u003c\/strong\u003e) in Q3 2024.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eSTRATA Skin Sciences, Inc. (SSKN) - VRIO Analysis: 9. Cash Position \u0026amp; Recent Capital Raising Capability\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Provides the necessary working capital to fund operations, ongoing litigation, and strategic initiatives like CPT code lobbying. The CMS recognition of expanded CPT codes is a key value driver, anticipated to \u003cstrong\u003etriple\u003c\/strong\u003e the covered US patient population.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Low; the ability to raise capital is common for public companies, but the terms matter.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low; it is a function of market access and investor sentiment.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Adequate; ended Q3 2025 with \u003cstrong\u003e$7.1 million\u003c\/strong\u003e in cash and recently closed a \u003cstrong\u003e$2.42 million\u003c\/strong\u003e registered direct offering in September 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e None; this is a necessary condition for survival, not a source of sustained advantage, though it helps weather near-term risks.\u003c\/p\u003e\n\u003cp\u003eKey financial metrics supporting the cash position and operational funding capacity:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue (Q3 2025 End\/Period)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash \u0026amp; Equivalents\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$7.1 million\u003c\/strong\u003e (as of Sept 30, 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegistered Direct Offering Gross Proceeds\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$2.42 million\u003c\/strong\u003e (September 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ3 2025 Total Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$6.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ3 2025 Net Loss\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.6 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross Margin\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e60%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eDetails on recent capital activity and operational metrics:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe September 2025 registered direct offering involved the sale of \u003cstrong\u003e1,097,547\u003c\/strong\u003e shares at a per share purchase price of \u003cstrong\u003e$2.204\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eNet proceeds from the offering are intended for working capital and general corporate purposes.\u003c\/li\u003e\n\u003cli\u003eGlobal recurring revenue for Q3 2025 was \u003cstrong\u003e$5.5 million\u003c\/strong\u003e, representing a \u003cstrong\u003e3%\u003c\/strong\u003e year-over-year increase.\u003c\/li\u003e\n\u003cli\u003eThe U.S. XTRAC install base stood at \u003cstrong\u003e838\u003c\/strong\u003e devices at the close of Q3 2025.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516256280725,"sku":"sskn-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/sskn-vrio-analysis.png?v=1740218566","url":"https:\/\/dcf-model.com\/pt\/products\/sskn-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}